Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Neuropharmacology. 2014 May 20;85:91–103. doi: 10.1016/j.neuropharm.2014.05.005

Fig. 3.

Fig. 3

Development of tolerance to the anti-absence activity of RO0711401 after the first 3 days of treatment. WAG/Rij rats were treated s.c. twice daily for 10 days with RO0711401 (10 mg/kg), VU0360172 (3 mg/kg), or the respective vehicles. A re-challenge with each of the two drugs was performed after 3 days of withdrawal. The incidence of SWDs at 1 h after the morning injection is shown. Values are means + S.E.M. P < 0.05 vs. the respective vehicles (*) or vs. VU0360172 (#).